Detalhe da pesquisa
1.
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.
Lancet Oncol
; 24(5): 483-495, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37080222
2.
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
BMC Cancer
; 23(1): 710, 2023 Jul 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37516867
3.
Methods for Inclusive Underwriting of Breast Cancer Risk with Machine Learning and Innovative Algorithms.
J Insur Med
; 50(1): 36-48, 2023 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37725502
4.
Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Br J Cancer
; 125(2): 190-199, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33824476
5.
Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma.
Hepatology
; 67(3): 1132-1149, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28862760
6.
GNS561, a new lysosomotropic small molecule, for the treatment of intrahepatic cholangiocarcinoma.
Invest New Drugs
; 37(6): 1135-1145, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-30778887
7.
Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma.
Liver Int
; 39(8): 1468-1477, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30963691
8.
Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data.
Future Oncol
; 15(11): 1219-1230, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30701988
9.
Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors.
Future Oncol
; 15(17): 1997-2007, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31084373
10.
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer.
Int J Cancer
; 143(8): 2053-2064, 2018 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29756206
11.
Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response.
Br J Cancer
; 118(2): 181-188, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29161241
12.
Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms.
Neuroendocrinology
; 107(1): 24-31, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29518779
13.
Efficacy and Safety of Sunitinib in Patients with Well-Differentiated Pancreatic Neuroendocrine Tumours.
Neuroendocrinology
; 107(3): 237-245, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-29991024
14.
Correction: Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.
Br J Cancer
; 125(3): 465, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34079081
15.
Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
Acta Oncol
; 55(9-10): 1168-1174, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27333436
16.
Reinvention of chemotherapy: drug conjugates and nanoparticles.
Curr Opin Oncol
; 27(3): 232-42, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25783982
17.
Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature.
Hepatology
; 59(6): 2228-37, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24443104
18.
Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors.
Invest New Drugs
; 33(6): 1206-16, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26377590
19.
High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
Histopathology
; 67(5): 664-76, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25809563
20.
Phase II study of mTORC1 inhibition by everolimus in neurofibromatosis type 2 patients with growing vestibular schwannomas.
J Neurooncol
; 122(2): 313-20, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25567352